drugset
drugset / Trial / NCT06205121

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

NCT06205121 ↗

Phase 2 Recruiting 96 enrolled Molecure S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.

Timeline

Start
2024-03-21
Primary completion
2027-08
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject 5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE Small molecule 25 mg Oral

Indications

pulmonary sarcoidosis